Inclusion Criteria:

• Participant has provided written informed consent and agrees to comply with the study protocol.
• Participant with PBC diagnosis.
• Participant for whom the treating physician has decided to start or participants who are currently receiving treatment with commercialized elafibranor.
• If a participant has a caregiver who agrees to complete the caregiver questionnaires, an informed consent should be collected from the caregiver before any data is collected.

Exclusion Criteria:

• Participant is currently participating or, plans to participate in an investigational drug study or medical device study containing active substance.
• Participant with known hypersensitivity to the product or to any of its excipients.
• Participant with mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.